Episode
Episode 162 - Arun Swaminathan - CEO at Coya Therapeutics
- Podcast
- The BioHub - by Avetix
- Published
- Apr 27, 2026
- Duration seconds
- 1637
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-162-arun-swaminathan-ceo-at-coya-therapeutics/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-162-arun-swaminathan-ceo-at-coya-therapeutics.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of The BioHub Podcast by Avetix , Ben sits down with Dr. Arun Swaminathan, CEO of Coya Therapeutics, a clinical-stage biotechnology company developing therapies designed to enhance regulatory T cell function and target systemic inflammation and neuroinflammation. Arun brings more than 20 years of healthcare leadership experience across corporate strategy, business development, operations, and deal-making. At Coya, he is helping lead the company’s work in severe neurodegenerative diseases, including ALS, Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease, with a focus on immunomodulatory and Treg-based therapeutic approaches. In this conversation, we discuss the evolving treatment landscape in neurodegeneration, the role of neuroinflammation in CNS drug development, what it takes to build and finance a clinical-stage biotech, and how combination therapeutic strategies could shape the next generation of disease-modifying treatments.